PLC
ZNTL icon

Peapod Lane Capital’s Zentalis Pharmaceuticals ZNTL Stock Holding History

Peapod Lane Capital’s Portfolio ZNTL Stock Details ZNTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$984K Sell
202,864
-164,004
-45% -$655K 0.66% 57
2026
Q1 		$835K Sell
366,868
-81,993
-18% -$212K 0.68% 53
2025
Q4 		$606K Sell
448,861
-116,510
-21% -$170K 0.52% 56
2025
Q3 		$854K Buy
565,371
+6,158
+1% +$9.23K 0.76% 50
2025
Q2 		$649K Buy
559,213
+795
+0.1% +$1.05K 0.65% 49
2025
Q1 		$888K Buy
+558,418
New +$1.2M 1% 37

Other funds holding ZNTL

5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Peapod Lane Capital's ZNTL Position: Q2 2026 in Review

Peapod Lane Capital reduced its Zentalis Pharmaceuticals (ZNTL) stake by 45% in Q2 2026, selling an estimated $655K and leaving 202,864 shares worth $984K. The position accounts for 0.66% of the portfolio, ranked #57.

Peapod Lane Capital first reported a position in ZNTL in Q1 2025 and has held it in 6 quarters since. 114 funds tracked by Wall St. Rank hold ZNTL as of Q2 2026.

  • Peapod Lane Capital held 202,864 shares of Zentalis Pharmaceuticals worth $984K as of Q2 2026.
  • Peapod Lane Capital sold 164,004 Zentalis Pharmaceuticals shares in Q2 2026, an estimated $655K.
  • Zentalis Pharmaceuticals made up 0.66% of Peapod Lane Capital's portfolio in Q2 2026, its #57 holding.
  • Peapod Lane Capital first reported a position in Zentalis Pharmaceuticals in Q1 2025 and has held it in 6 quarters since.
  • 114 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q2 2026.

Based on Peapod Lane Capital's 13F filing for Q2 2026, filed 27 Jul 2026.